Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06787339 2025-01-22

Calorite

Phase 2 Not yet recruiting

198 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03487666 2024-12-03

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Phase 2 Completed

45 enrolled 15 charts

Breast

Triple Negative Breast Neoplasms

NCT06700382 2024-11-25

NeoTNBCX

Recruiting

1,166 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06533384 2024-11-04

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Phase 3 Recruiting

310 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03872388 2024-10-02

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Phase 2 Terminated

6 enrolled 8 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

54 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06385990 2024-04-26

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Phase 2 Recruiting

53 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Breast

Triple Negative Breast Neoplasms

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

95 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Phase 2 Not yet recruiting

182 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

139 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04501523 2023-02-21

Apollo

Phase 2 Recruiting

460 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05390476 2022-11-04

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Phase 2 Unknown

126 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05438706 2022-06-30

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2 Unknown

70 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Phase 2 Unknown

100 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03044730 2020-07-13

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Phase 2 Unknown

30 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01112826 2020-05-27

SYSUCC-001

Phase 3 Completed

443 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03775928 2018-12-14

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

80 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03358004 2018-10-05

VICTOR3

Phase 2 Terminated

4 enrolled

Breast

Triple Negative Breast Neoplasms

NCT01642771 2017-04-19

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

Phase 3 Unknown

636 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01969032 2014-11-05

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer

Phase 2 Completed

41 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

EVOLVE-BDT

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

SASCIA

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

PLANET

TARMAC

CAPPA

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

NeoADAPT

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

PERSEVERE

Calorite

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

NeoTNBCX

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

PATHFINDER

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

BreastImmune03

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

FUTURE-SUPER

Apollo

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

FUTURE

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

SYSUCC-001

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

VICTOR3

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer